|
Envelope surface glycoprotein gp120
|
env
|
CD4-mediated endocytosis of HIV-1 gp120 results in MHC-II (HLA-DR) presentation to CD4+ T cells |
PubMed
|
|
env
|
CD4+ T cells infected with CCR5-tropic HIV-1 have significantly higher levels of activation-marker expression (e.g. CD25, CD71 and HLA-DR) than CD4+ T lymphocytes infected with CXCR4-tropic HIV-1 |
PubMed
|
|
env
|
HIV envelope protein gp120 can specifically inhibit CD4-dependent class II MHC-restricted T cell response to Ag |
PubMed
|
|
env
|
Genetic variability in HIV-1 gp120 affects its interactions with HLA-DR molecules and T cell receptor |
PubMed
|
|
env
|
Amino acid residues 42-49 in the V1 region of CD4 are involved in the interaction between HIV-1 gp120 and class II major histocompatibility complex molecules |
PubMed
|
|
Envelope surface glycoprotein gp160, precursor
|
env
|
Processing of HIV-1 gp160 to gp120 and gp41 is necessary for the association of HIV-1 envelope glycoproteins with class II MHC |
PubMed
|
|
env
|
Antibodies against cell surface molecules LFA-1, ICAM-1, HLA-DR, and CD28 inhibit the HIV-1 gp160-induced B cell differentiation response; gp160 also induces IL-6R and CD23 molecule expression on B cells |
PubMed
|
|
Envelope transmembrane glycoprotein gp41
|
env
|
Soluble HIV-1 gp41 enhancement effects on MHC class I and II antigen expression can be inhibited by soluble gp41-binding proteins of 45, 49 and 62 kD from human B cells |
PubMed
|
|
env
|
Soluble HIV-1 gp41 can selectively enhance MHC class I and II expression on human B cells, but does not increase expression of other cell surface antigens such as CD21 and CD54 (ICAM-1) |
PubMed
|
|
env
|
A 43-amino-acid sequence between amino acids 708 and 750 in the HIV-1 gp41(TM) cytoplasmic tail is required for efficient incorporation of HLA class II proteins into virions |
PubMed
|
|
Nef
|
nef
|
HIV-1 Nef impairs IL-4/GM-CSF-stimulated THP-1 differentiation towards immature DCs, which leads to the lower levels of CD11C, CD40, and HLA-DR protein expression from the cell surface |
PubMed
|
|
nef
|
Four large regions (residues 1-36, 66-97, 117-147, and 182-205) of HIV-1 Nef bind efficiently to eight HLA-DR molecules |
PubMed
|
|
nef
|
HIV-1 Nef-pulsed mDCs downregulate HLA-DR expression and upregulate CD25 and CCR7 expression in NK cells |
PubMed
|
|
nef
|
Nef-triggered MHCII endocytosis requires Rab5 activity and lyst function, whereas lysosomal trafficking of internalized MHCII molecules requires Rab7 activity |
PubMed
|
|
Pr55(Gag)
|
gag
|
Expression of CD80, CD83, CD86, and HLA-DR molecules are significantly downregulated in mature dendritic cells after transduction with ubiquitinated Gag compared to unubiquitinated Gag constructs |
PubMed
|
|
gag
|
Two peptides of the CA domain of HIV-1 Gag, VDRFYKTLRAEQASQ and DRFYKLTRAEQASQ, are presented on MHC II molecules of dendritic cells and have similar sensitivity for antigen-specific T cells |
PubMed
|
|
gag
|
Expression of MARCH-8 inhibits HLA-DR-mediated enhancement of mature Gag products internalization by downregulating cell surface HLA-DR |
PubMed
|
|
gag
|
The Gag late-budding domain PTAP motif and the cytosolic tails of the HLA-DR alpha and beta chains are required for HLA-DR-mediated Gag accumulation in late endosomal/multivesicular bodies (LE/MVB) |
PubMed
|
|
gag
|
Dynamin-dependent endocytosis is required for intracellular accumulation of HIV-1 Gag in presence of HLA-DR |
PubMed
|
|
gag
|
HIV-1 Gag virus-like particle-induced monocyte activation is shown by upregulation of molecules involved in antigen presentation (MHC II, CD80, CD86) and cell adhesion (CD54) |
PubMed
|
|
gag
|
HIV-1 Gag virus-like particles efficiently activate human monocyte-derived dendritic cells (MDDC) and induce MDDC maturation with an associated increase in the surface expression of CD80, CD86 and MHC classes I and II |
PubMed
|
|
gag
|
Human Leukocyte Antigen DR (HLA-DR), Major Histocompatibility Complex class II molecules (MHC-II) induce a relocation of Gag to late endosomal/multivesicular bodies (LE/MVB) and increase the accumulation of viral particles assembling intracellularly |
PubMed
|
|
gag
|
HIV-1 Gag expression is able to induce HLA-DR cell-surface localization in H78-C10.0 cells |
PubMed
|
|
gag
|
In human macrophages, HIV-1 Gag proteins co-localize with MHC II (HLA-DR), CD63, and Lamp1 in MHC II compartments |
PubMed
|
|
Tat
|
tat
|
Treatment of PBMCs with HIV-1 Tat significantly enhances the generation of monocytic myeloid-derived suppressor cells expressing no or very low levels of HLA-DR |
PubMed
|
|
tat
|
HIV-1 Tat upregulates HLA-DR expression in monocyte-derived dendritic cells and T cells, thereby driving T cell-mediated immune responses and activation |
PubMed
|
|
tat
|
HIV-1 Tat downregulates expression of MHC class II genes in antigen-presenting cells (APC) by inhibiting the transactivator of MHC class II genes, CIITA |
PubMed
|
|
Vpu
|
vpu
|
HIV-1 Vpu interacts with CD74 and modulates MHC II in HIV-1-infected cells |
PubMed
|
|
capsid
|
gag
|
HIV-1 CA co-localizes with HLA-DR in human monocyte-derived dendritic cells |
PubMed
|
|
gag
|
HIV-1 Capsid (p24) inhibits interferon gamma induced increases in HLA-DR and cytochrome B heavy chain mRNA levels in the human monocyte-like cell line THP1 |
PubMed
|